RIDDLE&CODE-GMBH
23.8.2022 10:17:11 CEST | Business Wire | Press release
Riddle&Code GmbH is pleased to announce John Calian as the new CEO of the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005122/en/
"I am grateful to have been selected as Riddle&Code's next CEO. We are an organisation led by a purpose – to onboard industrial machines to Web3. It is a privilege to lead a team dedicated to machine-driven token economies, enabling sustainable, green, resilient energy systems," said Calian. "That is the mission of our company. I will do my best to serve the team and our customers by enabling our leaders and people to do their best work."
This decision comes at a momentous time, as Riddle&Code evolves into a product-led service company specialising in Web3 infrastructure and establishing the unique RDDL Network blockchain, which provides the cornerstones for decentralised, secure, and trusted machine economies. Riddle&Code is preparing to be a key contributor to this network and aims to provide the best products, services, and solutions to make this vision flourish.
Working with enterprise partners such as Wien Energie, Daimler Mobility, Evonik, Litebit, and Telekom Innovation Laboratories (T-Labs), Riddle&Code has built an extensive portfolio of blockchain-powered software and hardware products across key industry segments, highlighted by renewable energy producers, electric vehicle manufacturers and large scale energy storage systems providers.
"We are at a natural turning point for the company, and John brings the leadership and expertise needed for Riddle&Code to enter this next phase. Our new purpose is to share our established knowledge and onboard as many industries as possible to Web3 to shape the future of interconnecting token economies with the RDDL Network. This goes way beyond the wildest ambitions of current token projects and energy tech companies." ~ Tom Fürstner, Founder and CTO of Riddle&Code.
The landscape for decentralised infrastructure is rapidly changing, and there has been an increase in demand for blockchain-based software systems due to the ongoing shift towards Web3. This new era requires industries to set up new operating and business models, combining old strengths with a new way of thinking.
Riddle&Code is now focused on being a key player in onboarding industries to Web3 and will provide specific products and services. Co-Founder and outgoing CEO Alexander Koppel will continue as Advisor to the CEO in the future and further support the company's mission. This announcement is the logical next step in the further evolution and continued progress of Riddle&Code and its subsidiary companies.
About Riddle&Code
Riddle&Code is a product-led services company specialising in onboarding industries to Web3. The company is the main driver for a world of interconnected token economies by enabling sustainable, green, and resilient machine industries. Riddle&Code offers various solutions to tailor industry-specific hardware wallets and an application suite to build on decentralised blockchains, mainly contributing to the RDDL Network blockchain protocol.
More information: www.riddleandcode.com
About the RDDL Network
The RDDL Network is a decentralised, industrial machine-powered blockchain protocol that uses a unique Proof-of Productivity (PoP) consensus mechanism that proves identity, data accuracy, and usage for all types of machines. It addresses infrastructure and standards as a whole and is designed to shape the future of interconnected token economies for the fourth industrial revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005122/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom